Serial intravascular ultrasound evaluation of the DESolve™ novolimus‐eluting bioresorbable coronary scaffold system

Abstract

IVUS serial evaluation of the novel DESolve BRS showed an increase in the device dimensions between baseline and 6 months, with concomitant enlargement of lumen dimensions and effective suppression of neointimal proliferation. At 18 months, no footprint of the scaffold was detected and the initial lumen enlargement was sustained.

Current perspectives on the role of bioresorbable scaffolds in the management of coronary artery disease

“…The DESolve Nx clinical study involving 126 patients showed a high device and procedural success and low rates of adverse events, including low device thrombosis (0.8%), through 24 months [51]. Serial intravascular ultrasound evaluation showed an increase in the device and lumen dimensions between baseline and six months, with no detectable footprints of the scaffold at 18 months [52]. Furthermore, in the DESolve PMCF study involving 102 patients with CAD, a low rate of TVF (3.0%) and device thrombosis (1.0%) was observed at 12 months [53].…”

Bioresorbable scaffolds: current concepts and future technology

“…However, the propensity matched analysis demonstrated no difference in clinic performance of ®DESolve compared to ®Absorb BVS at 1 year [19]. Serial intravascular ultrasound (IVUS) has revealed an increase in the device and lumen dimensions between baseline and 6 months, with no detectable footprints of the scaffold at 18 months [20]. At 5-year clinical and imaging follow-up of the DESolve Nx clinical study [21] no definite scaffold thrombosis was reported but cardiac deaths were 2.5% and TLR rate was 4.1% (Table 2).…”